Controlling porous titanium/soft tissue interactions with an innovative surface chemical treatment: Responses of macrophages and fibroblasts.


Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 29 12 2019
revised: 05 03 2020
accepted: 12 03 2020
entrez: 16 5 2020
pubmed: 16 5 2020
medline: 4 3 2021
Statut: ppublish

Résumé

In order to create a stable interface with the host tissue, porous implants are widely used to ensure the in-growth of the cells and the colonization of the implant. An ideal porous implant should have a 3D architecture that enables fast migration of incoming cells while not inducing a significant pro-inflammatory response by the immune cells. Moreover, in patients where the healing is impeded (patients with co-morbidities and metabolic diseases), porosity by itself is not enough for fast colonization, and the surface properties of the implant should also be controlled. In this study, we present a controlled oxidation-based surface treatment of microbead-based porous titanium implants which not only increases the colonization by connective tissue cells but also decreases the macrophage attachment. The treatment created a nanotextured surface on the implants with an acidic shift of isoelectric point (from 4.09 to 3.09) without endangering implant's mechanical integrity. The attachment and metabolic activity of activated macrophages were significantly lower on treated surfaces with an increase in the secretion of anti-inflammatory IL-1RA and a decrease in pro-fibrotic CCL-18. Human fibroblasts proliferated faster on the treated surfaces over 14 days with near complete colonization of the whole thickness of the implant with an accompanying an increase in the secretion of TGF-beta. The surface treated samples demonstrated partial filling of the entire pores. We demonstrated that the use of nanoscale surface treatments that can be applied to the whole internal surface of porous titanium implants can significantly alter both the immune response and the colonization of the implants and can be used to fine-tune and personalize implant interfaces according to patient needs.

Identifiants

pubmed: 32409027
pii: S0928-4931(19)34871-4
doi: 10.1016/j.msec.2020.110845
pii:
doi:

Substances chimiques

Chemokine CCL18 0
Interleukin 1 Receptor Antagonist Protein 0
Titanium D1JT611TNE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110845

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Julien Barthes (J)

INSERM UMR1121 "Biomaterials and Bioengineering", 11 Rue Humann, 67085 Strasbourg, France.

Martina Cazzola (M)

Politecnico di Torino, Corso duca degli Abruzzi 24, 10129 Torino, Italy.

Celine Muller (C)

INSERM UMR1121 "Biomaterials and Bioengineering", 11 Rue Humann, 67085 Strasbourg, France.

Camille Dollinger (C)

INSERM UMR1121 "Biomaterials and Bioengineering", 11 Rue Humann, 67085 Strasbourg, France.

Christian Debry (C)

INSERM UMR1121 "Biomaterials and Bioengineering", 11 Rue Humann, 67085 Strasbourg, France; Hôpitaux Universitaires de Strasbourg, Service Oto-Rhino-Laryngologie, Strasbourg, France.

Sara Ferraris (S)

Politecnico di Torino, Corso duca degli Abruzzi 24, 10129 Torino, Italy.

Silvia Spriano (S)

Politecnico di Torino, Corso duca degli Abruzzi 24, 10129 Torino, Italy. Electronic address: d002307@polito.it.

Nihal E Vrana (NE)

INSERM UMR1121 "Biomaterials and Bioengineering", 11 Rue Humann, 67085 Strasbourg, France; Spartha Medical, 14B rue de la Canardière, 67100 Strasbourg, France. Electronic address: evrana@sparthamedical.eu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH